This week in therapeutics




Licensing status

Publication and
contact information



IL-20; IL-20 receptor-a (IL20R1; IL20RA); cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A; CIP1)

Patient sample and cell culture studies suggest inhibiting IL-20 could help treat muscle-invasive bladder cancer. In human bladder cancer tissue, mRNA levels of IL-20 and its receptor IL20R1 were greater than those in healthy tissue. In cell-based assays, IL-20 stimulation increased migration and invasion of bladder cancer cell lines and expression of the cell cycle inhibitory protein CDKN1A compared with vehicle control administration. In the IL-20-stimulated cells, small interfering RNA against CDKN1A or IL20R1 prevented the increases in invasion and migration. Next steps could include developing pharmacological inhibitors.
Novo Nordisk A/S's NN8226, a neutralizing mAb against IL-20, is in Phase II testing to treat rheumatoid arthritis (RA).

SciBX 6(5); doi:10.1038/scibx.2013.109
Published online Feb. 7, 2013

Patent and licensing status unavailable

Lee, S.-J. et al. J. Biol. Chem.; published online Dec. 27, 2012;
Contact: Sung-Kwon Moon, Chungju National University, Chungbuk, South Korea